International Assets Investment Management LLC Makes New Investment in Hims & Hers Health, Inc. (NYSE:HIMS)

International Assets Investment Management LLC acquired a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 36,840 shares of the company’s stock, valued at approximately $6,790,000.

Several other institutional investors and hedge funds have also made changes to their positions in HIMS. Lake Street Private Wealth LLC boosted its stake in shares of Hims & Hers Health by 80.3% during the 3rd quarter. Lake Street Private Wealth LLC now owns 103,447 shares of the company’s stock worth $1,905,000 after purchasing an additional 46,076 shares during the last quarter. Venture Visionary Partners LLC acquired a new position in shares of Hims & Hers Health during the third quarter worth about $238,000. Heritage Wealth Management Inc. CA acquired a new position in shares of Hims & Hers Health during the third quarter worth $297,000. Means Investment CO. Inc. purchased a new position in Hims & Hers Health in the 3rd quarter valued at about $747,000. Finally, Cadent Capital Advisors LLC purchased a new position in Hims & Hers Health in the third quarter valued at about $1,310,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of recent research reports. Piper Sandler reaffirmed a “neutral” rating and set a $18.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, August 6th. Bank of America lifted their target price on Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Truist Financial boosted their target price on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, July 18th. Needham & Company LLC initiated coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 target price for the company. Finally, Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Eight investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $20.21.

Insider Buying and Selling

In other Hims & Hers Health news, insider Soleil Boughton sold 2,334 shares of Hims & Hers Health stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $17.30, for a total transaction of $40,378.20. Following the completion of the sale, the insider now owns 164,475 shares of the company’s stock, valued at approximately $2,845,417.50. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CFO Oluyemi Okupe sold 269,739 shares of the business’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $20.31, for a total transaction of $5,478,399.09. Following the completion of the transaction, the chief financial officer now directly owns 145,763 shares in the company, valued at approximately $2,960,446.53. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Soleil Boughton sold 2,334 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $17.30, for a total value of $40,378.20. Following the completion of the transaction, the insider now owns 164,475 shares of the company’s stock, valued at $2,845,417.50. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 858,665 shares of company stock valued at $15,148,890 over the last ninety days. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $18.85 on Friday. The company has a market cap of $4.05 billion, a price-to-earnings ratio of 235.56 and a beta of 1.06. The stock’s fifty day moving average price is $17.94 and its two-hundred day moving average price is $18.01. Hims & Hers Health, Inc. has a 52-week low of $5.76 and a 52-week high of $25.74.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The business had revenue of $315.65 million for the quarter, compared to analysts’ expectations of $302.43 million. During the same quarter last year, the business earned ($0.03) earnings per share. The firm’s quarterly revenue was up 51.8% compared to the same quarter last year. On average, equities analysts predict that Hims & Hers Health, Inc. will post 0.22 EPS for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.